OBESITY OR OVERWEIGHT

This study is testing whether adding a weight-loss drug (tirzepatide) to a standard ulcerative colitis drug (mirikizumab) works better than the colitis drug alone. It's for adults who have both moderately to severely active ulcerative colitis and obesity or overweight. The main g…

This early-stage study is testing an experimental injection called GZR18 in people who are overweight or obese. The main goals are to see how the injection affects how quickly the stomach empties and whether it changes how the body processes three common medications (digoxin, ros…

This study is testing a new weekly injection called RO7795068 to see if it helps people with obesity or overweight and type 2 diabetes lose weight and better control their blood sugar. About 1,600 participants will receive either the active drug or a placebo (dummy injection) for…

This study is testing a new weekly injection, called RO7795068, to see if it helps people with obesity or overweight lose weight and keep it off. It will involve about 2000 adults who do not have type 2 diabetes. The main goal is to see how much body weight participants lose afte…

This study is testing whether adding a weight-loss drug (tirzepatide) to a Crohn's disease drug (mirikizumab) works better than the Crohn's drug alone. It's for adults who have active Crohn's disease and are also overweight or have obesity. The main goal is to see if the combinat…